Fusion Antibodies PLC
20 July 2026
20 July 2026
Fusion Antibodies plc
("Fusion" or the "Company")
Grant of options
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company has granted 2,910,000 options (the "Options") over ordinary shares of 4 pence each in the Company ("Ordinary Shares") to certain Executive Directors and employees of the Company. The Options were granted pursuant to the Fusion Antibodies EMI and Unapproved Employee Share Option Scheme (the "Scheme"), adopted by the Company on 11 December 2017.
The Options have an exercise price of 10.30 pence per Option, being the closing mid-market price of an Ordinary Share on 17 July 2026, the business day prior to the date of grant. The Options will vest equally over a three-year period, with one third of the Options vesting on each anniversary following the grant date and subject to continuing employment only. Once vested, the Options can be exercised for a period of ten years from the grant date.
1,000,000 of the Options have been granted to the following Executive Directors of the Company:
|
Name |
Number of Options granted |
Existing options over Ordinary Shares held |
Total Options over Ordinary Shares held following grant |
|
Adrian Kinkaid, CEO |
600,000 |
900,000 |
1,500,000 |
|
Richard Buick, CSO |
400,000 |
680,000 |
1,080,000 |
Following the grant of the Options, the Company has options in issue over a total of 6,086,600 Ordinary Shares, representing 4.86 per cent. of the Company's issued share capital.
The table at the end of this announcement, which is provided in accordance with the requirements of the UK Market Abuse Regulation, provides further details.
Enquiries:
|
Fusion Antibodies plc |
|
|
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR |
|
Allenby Capital Limited |
Tel: +44 (0)20 3328 5656 |
|
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
|
|
Shard Capital Partners LLP |
|
|
Damon Heath (Joint Broker) |
Tel: +44 (0)207 186 9952 |
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com |
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
Investor Hub
We encourage all investors to share questions on this announcement via our investor hub https://investorhub.fusionantibodies.com/link/rJaa9e
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||||||||
|
a) |
Name |
|
|||||||||
|
2 |
Reason for the notification |
||||||||||
|
a) |
Position/status |
See 1(a) |
|||||||||
|
b)
|
Initial notification /Amendment |
Initial notification |
|||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a) |
Name |
Fusion Antibodies plc |
|||||||||
|
b) |
LEI |
213800KBAYRC9VOQ9V39 |
|||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Options over ordinary shares of 4p each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
|||||||||
|
b) |
Nature of the transaction |
Grant of options over ordinary shares |
|||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||
|
d) |
Aggregated information - Aggregated volume - Price |
N/A |
|||||||||
|
e) |
Date of the transaction |
20 July 2026 |
|||||||||
|
f) |
Place of the transaction |
Outside a trading venue |
|||||||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.